EFHD2

Across TCGA pan-cancer cohorts, EFHD2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated EFHD2 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher EFHD2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EFHD2 expression acts as an unfavorable survival marker.

LUSC and PRAD are the cancer types where EFHD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.253	0.676	.027	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

EFHD2–LUSC (OS)

Open the LUSC breakdown →